Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance

Diabetic Medicine

Volumn 17, Issue 4, 2000, Pages 259-268

  Sundkvist, Göran ^a,c   Dahlin, L B ^d   Nilsson, H ^a   Eriksson, K F ^a   Lindgarde F ^a   Rosen I ^a   Lattimer, S A ^b   Sima, A A F ^b   Sullivan, K ^b   Greene, D A ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d NONE

Author keywords

Human diabetes; IGT; Peripheral nerve function; Sorbitol; Sural nerve

Indexed keywords

INOSITOL; SORBITOL;

ARTICLE; DIABETIC NEUROPATHY; GLUCOSE TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELINATED NERVE; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; SURAL NERVE;

DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INOSITOL; MALE; MIDDLE AGED; NERVE DEGENERATION; NERVE FIBERS, MYELINATED; PROSPECTIVE STUDIES; REFERENCE VALUES; SENSORY THRESHOLDS; SORBITOL; SURAL NERVE; VIBRATION;

EID: 0034026555     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00261.x     Document Type: Article

References (43)

1. 1 Mayhaw JA, Gillon KRW, Hawthorne JN. Free and lipid inositiol, sorbitol, and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 1983; 24: 13-15.
2. 2 Hale PJ, Nattrass M, Silverman SH, Sennit C, Perkins CM, Udén A et al. Peripheral nerve concentrations of glucose, fructose, sorbitol and myo-inositol in diabetic and non-diabetic patients. Diabetologia 1987; 30: 464-467.
3. 3 Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Eng J Med 1988; 319: 542-548.
4. 4 Sima AAF, Bril V, Nathaniel V, McEwan AJ, Brown MB, Lattimer SA et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimen from patients with diabetic neuropathy treated with sorbinil. N Eng J Med 1988; 319: 548-555.
5. 5 Sima AAF, Prashar A, Nathaniel V, Bril V, Werb MR, Greene DA. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Diabetic Med 1993; 10: 115-121.
6. 6 Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs. Diabetes 1997; 46: S82-S89.
7. 7 Greene DA, Chakrabarti S, Lattimer SA, Sima AA. Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol. J Clin Invest 1987; 79: 1479-1485.
8. 8 Tomlinson DR, Mayer JH. Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol. Exp Neurol 1985; 89: 420-427.
9. +) -ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994; 94: 853-859.
10. 10 Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F, Mirrlees DJ. Aldose reductase inhibiton, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 1994; 37: 651-663.
11. 11 Jeffreys JGR, Palmano KP, Sharma AK, Thomas PK. Influence of dietary myoinositol on nerve conduction and inositol phospholipids in normal and diabetic rats. J Neurol Neurosurg Psychiatry 1978; 41: 333-339.
12. 12 Tomlinson DR. Polyols and myo-inositol in diabetic neuropathy - of mice and men. Mayo Clin Proc 1989; 64: 1030-1033.
13. 13 Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brian PC, Grina LA et al. Human diabetic endoneurinal sorbitol, fructose and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-596.
14. 14 Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11: 21-32.
15. 15 Stevens MJ, Lattimer SA, Feldman ED, Helton DS, Millington AAF, Sima AAF et al. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, motor conduction velocity in the streptozotocin-diabetic rat. Metabolism 1996; 45: 865-872.
16. 16 Low PA, Yao JK, Kishi Y, Tritschler HJ, Schmelzer JD, Zollman PJ et al. Peripheral nerve energy metabolism in experimental diabetic neuropathy. Neuroscience Res Com 1997; 21: 49-56.
17. 17 Eriksson KF, Nilsson H, Lindgärde F, Österlin S, Dahlin L-B, Lilja B et al. Diabetes mellitus but not impaired glucose tolerance is associated with dysfunction in peripheral nerves. Diabetic Med 1994; 11: 279-285.
18. 18 Sundkvist G, Lilja B, Nilsson H, Nilsson JÅ, Rosén I. Peripheral nerve dysfunction is reflected by loss of ankle reflexes but not by autonomic neuropathy in diabetic patients. Muscle Nerve 1997; 20: 740-743.
19. 19 Dahlin LB, Eriksson K-F, Sundkvist G. Persistent postoperative complaints after whole sural nerve biopsies in diabetic and non-diabetic subjects. Diabetic Med 1997; 14: 353-356.
20. 20 Greene DA, Brown MB. Validation of sural nerve fiber density and percent normal teased fibers as morphological endpoints in clinical trials of diabetic neuropathy. In Hotta N, Greene DA, Ward JD, Sima AAF, Boulton AJM. eds. Diabetic Neuropathy: New Concepts and Insights. Amsterdam: Exerpta Medica, Elsevier, 1995: 379-385.
21. 21 Sima AAF, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ et al. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diab Comp 1993; 7: 157-169.
22. 22 Jeppsson J-O, Jerntorp P, Sundkvist G, Englund H, Nylund V. Measurement of hemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 1986; 32: 1867-1872.
23. 23 Clements RS, Reynertson R. Myo-inositol metabolism in diabetes mellitus. Effect of insulin treatment. Diabetes 1977; 26: 215-221.
24. 24 Stevens MJ, Feldman EI, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabetic Med 1995; 12: 566-579.
25. 25 Giannini C. Ultrastructural morphometric analysis of human sural nerve biopsies. Diabetic Med 1996; 13: 675-676.
26. 26 Watkins PJ, Edmonds ME. Clinical features of diabetic neuropathy. In Pickup JC, Williams G. eds. Textbook of Diabetes Oxford: Blackwell Science, 1997.
27. 27 Stromberg T, Dahlin LB, Lundborg G. Hand problems in 100 vibrarion-exposed symptomatic male workers. Hand Surg (Br) 1996; 21B: 315-319.
28. 28 Birch R, Raji A. Repair of median and ulnar nerves. Primary suture is best. J Bone Joint Surg 1991; 73B: 154-157.
29. 29 Engkvist O, Wahren LK, Wallin G, Torebjork EBN. Effects of regional guanethidine block in posttraumatic cold intolerance in hand amputees. J Hand Surg 1985; 10B: 145-150.
30. 30 Gregersen G. Variations in motor conduction velocity produced by acute changes of the metabolic state in diabetic patients. Diabetologia 1968; 4: 273-277.
31. 31 Gregersen G. Diabetic neuropathy, influence of age, sex, metabolic control, and duration of diabetes on motor conduction velocity. Neurology 1967; 17: 972-980.
32. 32 Tomlinson DR. Aldose reductase inhibitors and the complications of diabetes mellitus. Diabetic Med 1993; 10: 214-230.
33. 33 Llewelyn JG, Gilbey SG, Thomas PK, King RHM, Muddle JR, Watkins PJ. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. A clinicopathological study. Brain 1991; 114: 867-892.
34. 34 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
35. 35 De Neeling JND, Beks PJ, Bertelsmann FW, Heine RJ, Bouter LM. Peripheral somatic nerve function in relation to glucose tolerance in an elderly Caucasian population: the Hoorn Study. Diabetic Med 1996; 13: 960-966.
36. 36 Drejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabetic Med 1998; 15: 97-112.
37. 37 Shindo H, Thomas TP, Larkin DD, Karihaloo AK, Inada H, Onaya T et al. Modulation of basal nitric oxide-dependent cyclic-GMP production by ambient glucose, myo-inositol, and protein kinase C in SH-SY5Y human neuroblastoma cells. J Clin Invest 1996; 97: 736-745.
38. 38 Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain 1985; 108: 861-880.
39. 39 Dyck PJ, Lais A, Karnes JL, O'Brien P, Rizza R. Fibre loss in primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986; 19: 425-439.
40. 40 Proceedings of a Consensus Development Conference on Standardized Measure in Diabetic Neuropathy. Morphological and biochemical measures. Neurology 1992; 42: 1825-1826.
41. 41 Russell JW, Karnes JL, Dyck PJ. Sural nerve myelinated fiber density differences associated with meaningful changes in clinical and electrophysiologic measurement. J Neurol Sci 1996; 135: 114-117.
42. 42 Midroni G, Bilbao JM. Chapter 3. Quantitative techniques. In Biopsy Diagnosis of Peripheral Neuropathy, Boston: Butterworth-Heinemann, 1995: 37.
43. 43 Thomas PK. Nerve biopsy. Diabetic Med 1997; 14: 345-346.